

Measuring Value in New Health Technology Assessments



Joanne Fitzgerald
Executive Director, Policy
and Classification,
Independent Hospital
Pricing Authority



Colleen Jen
Executive Director
Strategy and Planning,
Metro North Hospital
Health Service



Prof Ross Crawford
Professor of Orthopaedic
Research at Queensland
University of Technology



Alison Verhoeven
Deputy Director of
Orthopaedics, The Prince
Charles Hospital



Jennifer Doggett
Senior Consultant –
Health, CMAX Advisory



Alastair McLean
Director of Marketing and
Business Development,
Joint Replacement &
Robotics, Stryker South
Pacific



We acknowledge First Australian peoples and recognise their continuous connection to culture, community and Country.



Our Program

- *Joanne Fitzgerald, Independent Hospital Pricing Authority*
How new technology is currently assessed and what is proposed in the National Health Reform Agreement.
- *Colleen Jen, Professor Ross Crawford*
Robotics case study from Metro North Hospital and Health Service.
- *Alison Verhoeven, AHHA*
Recommendations: Measuring value in new health technology assessments.
- *Jennifer Doggett, CMAX Advisory*
Q&A.
- *Alistair McLean, Stryker*
Closing remarks.



Australian Centre for
**Value-Based
Health Care**

INSERT IHPA SLIDES

INSERT METRO NORTH SLIDES
or USE FOLLOWING
PLACEHOLDER



Metro North

Hospital and Health Service

deeble 
institute **issues brief**
Deeble Institute for Health Policy Research

no: 37

date: 24/08/2020

title **Measuring value in new health technology
assessments: a focus on robotic surgery in public
hospitals**

Robotics Case Study – Metro North HHS

Recommendations from Issues Brief 37



no: 37

date: 24/08/2020

title

Measuring value in new health technology assessments: a focus on robotic surgery in public hospitals

Recommendations:

The proposed national approach to HTA is welcome:

- Will provide clarity and consistency
- Will ensure public hospital patients across Australia have more equitable access to the best possible care.



Australian Centre for
**Value-Based
Health Care**

Recommendations:

Evidence to support the value of new technologies such as robotic surgery must include:

- Costs.
- Clinical outcomes.
- Outcomes that matter to patients.

This will require:

- Standardised data collection;
- More public ownership, sharing and reporting of data,
- More engagement of patients in determining outcomes that matter to them.

Recommendations:

Value for money, or 'real' value?

Funding models need to consider outcomes that matter to patients as well as cost efficiencies.

HTA that take into account outcomes that matter to patients is required to inform funding decisions.



Recommendations:

Clinician leadership and engagement with overall hospital and health system objectives is essential in identifying and activating access to new technologies in the public hospital system.

Recommendations:

Equity must be at the core of decision-making in public hospitals.

HTA must consider:

- Are the right patients receiving the right treatment?
- Value is only achieved across the whole health system if we aim for equity.



Australian Centre for
**Value-Based
Health Care**



stryker[®]



Metro North
Hospital and Health Service

Q&A

INSERT STRYKER SLIDES or USE
FOLLOWING PLACEHOLDER

no: 37

date: 24/08/2020

title **Measuring value in new health technology
assessments: a focus on robotic surgery in public
hospitals**

Closing Remarks



Australian Centre for
**Value-Based
Health Care**

For more information, please visit the Australian Centre
for Value-Based Health Care website:

<https://valuebasedcareaustralia.com.au/>

Thank you for your attendance